Unnamed: 0,title,date,stock,sentiment
382847.0,"HC Wainwright & Co. Maintains Buy on Durect, Raises Price Target to $6",2020-05-27 07:05:00-04:00,DRRX,neutral
382848.0,84 Biggest Movers From Yesterday,2020-05-13 05:31:00-04:00,DRRX,neutral
382849.0,60 Stocks Moving In Tuesday's Mid-Day Session,2020-05-12 12:26:00-04:00,DRRX,neutral
382850.0,"Durect Q1 EPS $(0.050) Misses $(0.040) Estimate, Sales $2.800M May Not Compare To $7.190M Estimate",2020-05-11 16:10:00-04:00,DRRX,negative
382851.0,"The Week Ahead In Biotech: Virtual Conference Presentations, Clovis PDUFA Date In The Spotlight",2020-05-10 15:40:00-04:00,DRRX,neutral
382852.0,Shares of several companies in the healthcare space are trading lower in sympathy with the overall market on continued downward momentum caused by the coronavirus. The virus has had a negative impact on the global economy.,2020-03-16 10:18:00-04:00,DRRX,negative
382853.0,92 Biggest Movers From Yesterday,2020-03-05 04:41:00-05:00,DRRX,neutral
382854.0,60 Stocks Moving In Wednesday's Mid-Day Session,2020-03-04 12:11:00-05:00,DRRX,neutral
382855.0,DURECT shares are trading higher after the company reported better-than-expected Q4 sales results.,2020-03-04 08:33:00-05:00,DRRX,positive
382856.0,"The Daily Biotech Pulse: Takeda Jumps Into The COVID-19 Fray, Exact Sciences Buys Cancer Diagnostics Companies",2020-03-04 07:37:00-05:00,DRRX,negative
382857.0,38 Stocks Moving in Wednesday's Pre-Market Session,2020-03-04 07:18:00-05:00,DRRX,neutral
382858.0,10 Stocks Moving In Tuesday's After-Hours Session,2020-03-03 16:47:00-05:00,DRRX,neutral
382859.0,DURECT shares are trading higher after the company reported better-than-expected Q4 sales results.,2020-03-03 16:33:00-05:00,DRRX,positive
382860.0,CORRECTION: Synacor Sees Q1 Sales $21.5M-$23.5M vs $24.8M Estimate; FY20 Sales $95M-$102M vs $100.1M Est.; Initial Headline Was Posted With Ticker DRRX; This Was An Error,2020-03-03 16:18:00-05:00,DRRX,negative
382861.0,"Durect Q4 EPS $(0.02), Inline, Sales $26.8M Beat $10.91M Estimate",2020-03-03 16:17:00-05:00,DRRX,neutral
382862.0,"The Daily Biotech Pulse: GenMark Diagnostics Ships COVID-19 Test Kits, Karyopharm To Offer Shares, And More",2020-03-03 07:51:00-05:00,DRRX,positive
382863.0,"The Week Ahead In Biotech: COVID-19 Stocks In The Spotlight, Earnings Taper Off",2020-02-29 14:52:00-05:00,DRRX,neutral
382864.0,Durect shares are trading higher. Not seeing any news to justify the price action.,2020-02-21 11:55:00-05:00,DRRX,positive
382865.0,Durect shares are trading higher. Not seeing any company-specific news to justify the price action.,2020-02-11 11:37:00-05:00,DRRX,positive
382866.0,"B. Riley Initiates Coverage On Durect with Buy Rating, Announces $5 Price Target",2020-01-31 06:30:00-05:00,DRRX,neutral
382867.0,70 Biggest Movers From Yesterday,2020-01-31 05:24:00-05:00,DRRX,neutral
382868.0,4 Specialty & Generic Drug Manufacturer Stocks Moving In Monday's After-Market Session,2020-01-27 23:48:00-05:00,DRRX,neutral
382869.0,36 Healthcare Stocks Moving In Monday's After-Market Session,2020-01-27 23:41:00-05:00,DRRX,neutral
382870.0,20 Specialty & Generic Drug Manufacturer Stocks Moving In Monday's Session,2020-01-27 12:26:00-05:00,DRRX,neutral
382871.0,82 Biggest Movers From Yesterday,2020-01-22 04:18:00-05:00,DRRX,neutral
382872.0,5 Drug Manufacturersâ€”Specialty & Generic Stocks Moving In Tuesday's After-Market Session,2020-01-21 23:34:00-05:00,DRRX,neutral
382873.0,29 Healthcare Stocks Moving In Tuesday's After-Market Session,2020-01-21 23:28:00-05:00,DRRX,neutral
382874.0,55 Stocks Moving In Tuesday's Mid-Day Session,2020-01-21 12:14:00-05:00,DRRX,neutral
382875.0,"Durect shares are trading lower in sympathy with the broader market as anxiety around the coronavirus outbreak in China spreads to global markets. NOTE: An FDA AdCom panel voted to discuss an NDA for POSIMIR, 6 voted for, and 6 voted against",2020-01-21 11:35:00-05:00,DRRX,positive
382876.0,38 Stocks Moving In Friday's Mid-Day Session,2020-01-17 12:28:00-05:00,DRRX,neutral
382877.0,"The Daily Biotech Pulse: Novo Nordisk's Ozempic Receives Label Expansion For Cardiovascular Events, Adcom Disappointment Inflicts Pain On Durect Shares",2020-01-17 08:07:00-05:00,DRRX,negative
382878.0,DURECT Shares To Resume Trade At 7:15 a.m. EST,2020-01-17 06:51:00-05:00,DRRX,positive
382879.0,"DURECT Reports FDA  Anesthetic and Analgesic Drug Products Advisory Committee Met Thurs. To Discuss Class 2 New Drug Application for POSIMIR; 6 AdCom Members Voted To Recommend Efficacy, Safety, 6 Voted Against Recommendation",2020-01-17 06:47:00-05:00,DRRX,positive
382880.0,"The Daily Biotech Pulse: Osmotica Soars On Insider Buys, Ultragenyx's Partnered Rare Disease Drug Moves Into Clinics",2020-01-16 07:22:00-05:00,DRRX,neutral
382881.0,DURECT Issues Press Release Highlighting Halt In Stock Ahead Of FDA AdCom Panel To Discuss POSIMIR For Post-Surgical Analgesia,2020-01-16 07:05:00-05:00,DRRX,neutral
382882.0,DURECT Shares Halted News Pending,2020-01-16 06:55:00-05:00,DRRX,positive
382883.0,Durect shares are trading higher. The stock moved higher following unusual interest in next month's $2.5 call contract.,2020-01-15 10:11:00-05:00,DRRX,positive
382884.0,Durect Option Alert: Feb 21 $2.5 Calls at the Ask: 600 @ $0.75 vs 1392 OI; Earnings 3/5 After Close [est] Ref=$2.5,2020-01-15 09:30:00-05:00,DRRX,positive
382885.0,34 Healthcare Stocks Moving In Wednesday's Pre-Market Session,2020-01-15 08:10:00-05:00,DRRX,neutral
382886.0,"The Week Ahead In Biotech: JPMorgan Healthcare Conference, FDA Panel Reviews Opioid Pain Drugs, I-Mab's IPO",2020-01-12 17:05:00-05:00,DRRX,negative
382887.0,Durect shares are trading lower. Not seeing any company-specific news to justify the price action.,2020-01-09 14:43:00-05:00,DRRX,neutral
382888.0,53 Biggest Movers From Friday,2020-01-06 05:30:00-05:00,DRRX,neutral
382889.0,30 Stocks Moving In Friday's Mid-Day Session,2020-01-03 12:29:00-05:00,DRRX,neutral
382890.0,65 Biggest Movers From Yesterday,2020-01-03 04:36:00-05:00,DRRX,neutral
382891.0,Mid-Afternoon Market Update: Signet Jewelers Falls Following Wells Fargo Downgrade; Trillium Therapeutics Shares Surge,2020-01-02 14:35:00-05:00,DRRX,positive
382892.0,42 Stocks Moving In Thursday's Mid-Day Session,2020-01-02 12:13:00-05:00,DRRX,neutral
382893.0,Mid-Day Market Update: Dow Rises 170 Points; Synthesis Energy Systems Shares Jump,2020-01-02 12:05:00-05:00,DRRX,positive
382894.0,Mid-Morning Market Update: Markets Open Higher; Imagination Technologies Signs New Deal With Apple,2020-01-02 10:20:00-05:00,DRRX,neutral
382895.0,Durect shares are trading lower after the company announced DUR-928 did not demonstrate benefit over placebo in Phase 2a psoriasis trial. The company is discontinuing development.,2020-01-02 09:26:00-05:00,DRRX,negative
382896.0,DURECT Corporation Announces DUR-928 Did Not Demonstrate Benefit Over Placebo In Phase 2a Psoriasis Trial; Co. To Discontinue Development,2020-01-02 09:06:00-05:00,DRRX,negative
382897.0,"The Daily Biotech Pulse: Canadian Approval For Amarin's Vascepa, Innate Pharma's Blood Cancer Drug Accepted For Review In Europe",2020-01-02 08:46:00-05:00,DRRX,negative
382898.0,63 Biggest Movers From Tuesday,2020-01-02 05:05:00-05:00,DRRX,neutral
382899.0,Attention Biotech Investors: Mark Your Calendar For These January PDUFA Dates,2020-01-01 18:00:00-05:00,DRRX,neutral
382900.0,38 Stocks Moving In Tuesday's Mid-Day Session,2019-12-31 12:18:00-05:00,DRRX,neutral
382901.0,38 Healthcare Stocks Moving In Monday's Pre-Market Session,2019-12-30 08:21:00-05:00,DRRX,neutral
382902.0,"Week Ahead In Biotech: PDUFA Date Ahead For Astra Zeneca, Merck's Lynparza, Pending Clinical Readouts In Focus",2019-12-29 18:38:00-05:00,DRRX,neutral
382903.0,Durect Option Alert: Jul 17 $5 Puts Sweep (9) near the Bid: 500 @ $2.5 vs 0 OI; Ref=$3.109,2019-12-27 10:40:00-05:00,DRRX,positive
382904.0,"The Daily Biotech Pulse: Flexion Receives FDA Nod For Zilretta Label Expansion, Astellas Goes Shopping",2019-12-27 07:59:00-05:00,DRRX,neutral
382905.0,"The Daily Biotech Pulse: Qiagen Opts To Stay Solo Following Strategic Review, Spectrum Slumps On Negative Data, Microbot Medical To Offer Shares",2019-12-26 07:55:00-05:00,DRRX,negative
382906.0,"The Daily Biotech Pulse: NewLink Genetics Licenses Ovarian Cancer Dug, Correvio Awaits FDA Verdict",2019-12-24 07:24:00-05:00,DRRX,negative
382907.0,78 Biggest Movers From Yesterday,2019-12-24 04:32:00-05:00,DRRX,neutral
382908.0,Stocks That Hit 52-Week Highs On Monday,2019-12-23 10:20:00-05:00,DRRX,neutral
382909.0,"Cantor Fitzgerald Assumes Durect at Overweight, Announces $5 Price Target",2019-11-18 06:35:00-05:00,DRRX,negative
382910.0,Durect Corporation Announces Results From Phase 2A Clinical Trial Of DUR-928 In Alcoholic Hepatitis Patients In A Late-breaking Presentation At The Liver Meeting; All Patients Treated With DUR-928 In Trial Survived 28-Day Follow-Up Period,2019-11-12 08:48:00-05:00,DRRX,positive
382911.0,"The Daily Biotech Pulse: Reata, Kadmon Clinical Readouts, Apyx Medical's Earnings Beat",2019-11-12 07:20:00-05:00,DRRX,neutral
382912.0,"The Week Ahead In Biotech: Adcom Test For Amarin's Fish Oil Pill, Agile Awaits FDA Verdict",2019-11-10 16:08:00-05:00,DRRX,positive
382913.0,"Durect Q3 EPS $(0.01) Misses $0.02 Estimate, Sales $10.8M Miss $15.7M Estimate",2019-11-04 16:27:00-05:00,DRRX,negative
382914.0,DURECT Reports DUR-928 Phase 2a Study Results Selected For Late-Breaking Oral Presentation At 2019 The Liver Meeting,2019-10-21 10:14:00-04:00,DRRX,neutral
382915.0,Durect shares are trading higher on seemingly no company-specific news.,2019-10-17 11:53:00-04:00,DRRX,neutral
382916.0,DURECT Announces Completion of Enrollment in its Phase 2a Clinical Trial of DUR-928 in Psoriasis and 50% Enrollment in its Phase 1b DUR-928 Clinical Trial in NASH,2019-10-07 08:12:00-04:00,DRRX,neutral
382917.0,Durect shares are trading higher after the company announced the FDA Advisory Committee plans to meet to review POSIMIR for the treatment of post-surgical pain.,2019-10-02 11:54:00-04:00,DRRX,negative
382918.0,DURECT Announces FDA Advisory Committee Meeting To Review POSIMIR For The Treatment Of Post-Surgical Pain; Meeting Scheduled For Jan. 16,2019-10-02 08:03:00-04:00,DRRX,negative
382919.0,Durect Corp shares are trading lower likely on profit taking after the stock has seen continuous upward momentum over the last 30 days. Not seeing any news to justify the price action.,2019-09-30 10:10:00-04:00,DRRX,positive
382920.0,52 Biggest Movers From Friday,2019-09-30 03:39:00-04:00,DRRX,neutral
382921.0,Shares of small-cap drugmaker Durect are trading lower. Shares have rallied this month and are potentially selling off.,2019-09-27 15:35:00-04:00,DRRX,positive
382922.0,"Top 10 Most Overbought Stocks Via Benzinga Pro's Screener Tool For Wed., September 25, 2019",2019-09-25 13:54:00-04:00,DRRX,positive
382923.0,Durect shares are trading higher despite no company-specific news. The stock has rallied approximately 45% in the past month.,2019-09-25 12:39:00-04:00,DRRX,positive
382924.0,"The Daily Biotech Pulse: Sandoz Recalls Ulcer Drug, Anchiano Strikes Agreement With ADT Pharma, Proteon Announces Reverse Merger",2019-09-24 08:12:00-04:00,DRRX,positive
382925.0,"Top 10 Most Overbought Stocks Via Benzinga Pro's Screener Tool For Mon, September 23, 2019",2019-09-23 13:45:00-04:00,DRRX,positive
382926.0,Stocks That Hit 52-Week Highs On Monday,2019-09-23 12:51:00-04:00,DRRX,neutral
382927.0,34 Stocks Moving In Monday's Mid-Day Session,2019-09-23 12:37:00-04:00,DRRX,neutral
382928.0,Durect shares are trading higher. Not seeing any news to justify the price action. The stock has seen continued upward momentum over the past 3 months.,2019-09-23 10:37:00-04:00,DRRX,positive
382929.0,Mid-Afternoon Market Update: U.S. Stocks Turn Lower; Roku Shares Plummet,2019-09-20 14:41:00-04:00,DRRX,neutral
382930.0,Shares of several drug companies are trading higher after Senate Majority Leader McConnell suggested a new Democratic drug price reform proposal would be dead on arrival.,2019-09-20 13:00:00-04:00,DRRX,negative
382931.0,Durect shares are trading higher. Not seeing any news to justify the price action.,2019-09-20 11:54:00-04:00,DRRX,positive
382932.0,10 Biggest Price Target Changes For Wednesday,2019-09-18 08:21:00-04:00,DRRX,neutral
382933.0,"Stifel Nicolaus Maintains Hold on Durect, Raises Price Target to $2.1",2019-09-18 08:03:00-04:00,DRRX,neutral
382934.0,"The Daily Biotech Pulse: NewLink Genetics Rallies, Breakthrough Designation For Roche, IGM Biosciences Debuts",2019-09-18 07:39:00-04:00,DRRX,neutral
382935.0,"Stifel Maintains Hold on Durect, Raises Price Target to $2.1",2019-09-18 06:59:00-04:00,DRRX,neutral
382936.0,Stocks That Hit 52-Week Highs On Tuesday,2019-09-17 10:40:00-04:00,DRRX,neutral
382937.0,Durect shares are trading higher after the company announced the completion of its Phase 2a Trial of DUR-928 for patients with alcoholic hepatitis.,2019-09-17 08:29:00-04:00,DRRX,positive
382938.0,DURECT Reports Completion Of Phase 2a Trial Of DUR-928 In Patients With Alcoholic Hepatitis,2019-09-17 08:01:00-04:00,DRRX,neutral
382939.0,Stocks That Hit 52-Week Highs On Monday,2019-09-09 12:43:00-04:00,DRRX,neutral
382940.0,64 Biggest Movers From Friday,2019-09-09 05:43:00-04:00,DRRX,neutral
382941.0,Stocks That Hit 52-Week Highs On Friday,2019-09-06 12:23:00-04:00,DRRX,neutral
382942.0,46 Stocks Moving In Friday's Mid-Day Session,2019-09-06 12:09:00-04:00,DRRX,neutral
382943.0,"Benzinga's Top Upgrades, Downgrades For September 6, 2019",2019-09-06 09:37:00-04:00,DRRX,positive
382944.0,Durect shares are trading higher after Cantor Fitzgerald initiated coverage on the stock with an Overweight rating and a price target of $5 per share.,2019-09-06 08:35:00-04:00,DRRX,positive
382945.0,16 Healthcare Stocks Moving In Friday's Pre-Market Session,2019-09-06 08:31:00-04:00,DRRX,neutral
382946.0,"Cantor Fitzgerald Initiates Coverage On Durect with Overweight Rating, Announces $5 Price Target",2019-09-06 07:49:00-04:00,DRRX,negative
382947.0,"The Daily Biotech Pulse: Puma Leaps, Aerie Borrows, Hepion Back In Nasdaq's Good Books",2019-09-04 07:08:00-04:00,DRRX,positive
382948.0,Stocks That Hit 52-Week Highs On Tuesday,2019-08-27 10:30:00-04:00,DRRX,neutral
382949.0,"The Daily Biotech Pulse: Nuvectra Explores Strategic Options, J&J To Contend Opioid Ruling, Sesen Bio Gets New CFO",2019-08-27 07:29:00-04:00,DRRX,positive
382950.0,Stocks That Hit 52-Week Highs On Monday,2019-08-26 10:19:00-04:00,DRRX,neutral
382951.0,Durect shares are trading higher on seemingly no company-specific news.,2019-08-22 14:42:00-04:00,DRRX,neutral
382952.0,42 Healthcare Stocks Moving In Wednesday's After-Market Session,2019-08-07 21:24:00-04:00,DRRX,neutral
382953.0,"Top 10 Most Overbought Stocks Via Benzinga Pro's Screener Tool For Fri., August 7, 2019",2019-08-07 12:56:00-04:00,DRRX,positive
382954.0,Shares of several healthcare companies are trading lower in sympathy with the overall market.,2019-08-07 10:31:00-04:00,DRRX,positive
382955.0,"Top 10 Most Overbought Stocks Via Benzinga Pro's Screener Tool For Fri., August 2, 2019",2019-08-02 14:05:00-04:00,DRRX,positive
382956.0,Durect shares are trading lower after the company reported worse-than-expected Q2 sales results.,2019-08-01 17:13:00-04:00,DRRX,neutral
382957.0,"Durect Q2 EPS $(0.04), Inline, Sales $3.985M Miss $4.02M Estimate",2019-08-01 17:08:00-04:00,DRRX,negative
382958.0,"Top 10 Most Overbought Stocks Via Benzinga Pro's Screener Tool For Wed., July 30, 2019",2019-07-31 13:10:00-04:00,DRRX,positive
382959.0,28 Healthcare Stocks Moving In Today's Pre-Market Session,2019-07-26 10:09:00-04:00,DRRX,neutral
382960.0,"Top 10 Most Overbought Stocks Via Benzinga Pro's Screener Tool For Tue., July 23, 2019",2019-07-23 13:52:00-04:00,DRRX,positive
382961.0,"Benzinga Pro's Top 10 Most-Searched Tickers For Morning of Tuesday, July 23, 2019",2019-07-23 11:09:00-04:00,DRRX,positive
382962.0,58 Biggest Movers From Yesterday,2019-07-23 05:39:00-04:00,DRRX,neutral
382963.0,Mid-Afternoon Market Update: Peak Resorts Climbs Following Acquisition News; Cadence Bancorp Shares Plummet,2019-07-22 14:30:00-04:00,DRRX,positive
382964.0,42 Stocks Moving In Monday's Mid-Day Session,2019-07-22 12:41:00-04:00,DRRX,neutral
382965.0,Durect shares are trading higher after the company and Gilead entered into a license agreement for long-acting Injectable HIV Investigational products. The company will receive $25 million with the potential of obtaining up to $75 million.,2019-07-22 12:23:00-04:00,DRRX,positive
382966.0,DURECT Soars On Out-Licensing Deal With Gilead For Up To $170M,2019-07-22 09:23:00-04:00,DRRX,neutral
382967.0,DURECT And Gilead Enter Into License Agreement For Long-Acting Injectable HIV Investigational Product; DURECT To Receive Upfront Payment Of $25M With Potential For Up To $75M In Development And Regulatory Milestones,2019-07-22 08:03:00-04:00,DRRX,positive
382968.0,DURECT Announces FDA Agreed To File  Full Response To POSIMIR Complete Response Letter As Complete Class 2 Resubmission,2019-07-17 08:02:00-04:00,DRRX,positive
382969.0,DURECT Reports FDA Submission Of Full Response to PSIMIR Complete Response Letter,2019-06-27 08:36:00-04:00,DRRX,neutral
382970.0,"The Daily Biotech Pulse: Decision Day For Regeneron-Sanofi, Vermillion Offering, PDL BioPharma CFO to Depart",2019-06-26 07:19:00-04:00,DRRX,neutral
382971.0,DURECT Receives Approval From Nasdaq For Transfer Of Listing To Nasdaq Capital Market,2019-06-25 16:31:00-04:00,DRRX,positive
382972.0,"DURECT Reports Completion Of 90 mg Severe Cohort, Dose Escalation Committee Approval To Commence 150 mg Dosing In Patients With Severe Alcoholic Hepatitis In Ongoing DUR-928 Phase 2a AH Trial",2019-06-18 08:08:00-04:00,DRRX,negative
382973.0,"The Daily Biotech Pulse: Daiichi's Positive Breast Cancer Trial, Supernus Slumps, Axovant Reverse Split",2019-05-08 07:53:00-04:00,DRRX,negative
382974.0,"Durect Q1 EPS $(0.04) Beats $(0.05) Estimate, Sales $4.131M Beat $3.5M Estimate",2019-05-07 18:04:00-04:00,DRRX,neutral
382975.0,"The Daily Biotech Pulse: Osmotica Flies, Catalyst Plummets, GW Pharma On Track To File For Expanded Use Of Epidiolex",2019-05-07 08:20:00-04:00,DRRX,neutral
382976.0,DURECT Reports Patient Enrollment In Phase 1b Trial Of Oral DUR-928 In Patients with NASH,2019-03-27 08:03:00-04:00,DRRX,neutral
382977.0,DURECT Reports Patient Dosing In Phase 2a Proof-Of-Concept Trial Of Topical DUR-928 In Patients With Mild To Moderate Plaque Psoriasis,2019-03-21 08:05:00-04:00,DRRX,neutral
382978.0,"Durect Q4 EPS $(0.05), Inline, Sales $3.627M Miss $3.77M Estimate",2019-03-07 16:47:00-05:00,DRRX,negative
382979.0,"Daily Biotech Pulse: Allergan's Depression Drug Flunks Late-Stage Trial, Apellis Offering, ShockWave Medical IPO",2019-03-07 07:48:00-05:00,DRRX,negative
382980.0,DURECT Announces Plans To Submit To FDA A Full Response To POSIMIR Complete Response Letter,2019-02-27 07:14:00-05:00,DRRX,neutral
382981.0,DURCET shares are trading lower after the company announced it would discontinue its primary sclerosing colangitis trial.,2019-01-07 10:54:00-05:00,DRRX,neutral
382982.0,DURECT to Discontinue its Primary Sclerosing Colangitis Trial,2019-01-07 07:38:00-05:00,DRRX,neutral
382983.0,DURECT Corporation Announces Investor Call To Provide Corporate Update Scheduled For Jan. 7,2019-01-03 16:31:00-05:00,DRRX,neutral
382984.0,"The Daily Biotech Pulse: Proteostasis Delays Data, Akron Gets New CEO, Pfizer Halts Vaccine Trial",2018-12-21 07:58:00-05:00,DRRX,neutral
382985.0,"Stocks Which Set New 52-Week Low Yesterday, Tues., Dec. 20, 2018",2018-12-20 11:33:00-05:00,DRRX,negative
382986.0,"Stocks Which Set New 52-Week Low Yesterday, Tues., Dec. 18, 2018",2018-12-19 12:43:00-05:00,DRRX,negative
382987.0,DURECT Highlights Commercial Launch Plans For PERSERIS ER Injectable Suspension For Treatment Of Schizophrenia In Adults,2018-12-19 08:05:00-05:00,DRRX,neutral
382988.0,"The Daily Biotech Pulse: Pfizer-Glaxo Set Up Consumer Health Care Venture, New Patent For Adamas",2018-12-19 07:46:00-05:00,DRRX,positive
382989.0,"The Daily Biotech Pulse: Puma Aces Late-Stage Trial, Chinese Cheer For FibroGen, J&J $5B Buyback Plan",2018-12-18 08:00:00-05:00,DRRX,positive
382990.0,"Stocks Which Set New 52-Week Low Yesterday, Thurs., Dec. 13, 2018",2018-12-14 11:03:00-05:00,DRRX,negative
382991.0,"The Daily Biotech Pulse: Axovant In-Licenses 2 Gene Therapies, Agile To Undertake Additional Study Of Contraceptive Patch",2018-12-14 07:47:00-05:00,DRRX,neutral
382992.0,"The Daily Biotech Pulse: Legal Victory For Boston Scientific, Alder Gets New CFO, FDA Go-Ahead For BioXcel",2018-12-12 08:07:00-05:00,DRRX,positive
382993.0,"The Daily Biotech Pulse: Management Change At Merck, Jazz Buyback, Arrowhead Earnings",2018-12-11 08:22:00-05:00,DRRX,neutral
382994.0,"Stocks Which Set New 52-Week Low The Last Trading Session, Fri., Dec. 7, 2018",2018-12-10 11:01:00-05:00,DRRX,negative
382995.0,"Stocks Which Set New 52-Week Low Yesterday Tues., Nov. 27, 2018",2018-11-28 11:54:00-05:00,DRRX,negative
382996.0,"Stocks Which Set New 52-Week Low Yesterday, Mon., Nov. 26, 2018",2018-11-27 11:26:00-05:00,DRRX,negative
382997.0,"Stocks Which Set New 52-Week Low Yesterday, Tues., Nov. 20, 2018",2018-11-21 08:50:00-05:00,DRRX,negative
382998.0,"The Daily Biotech Pulse: Mylan Recalls Blood Pressure Drug, Heat Biologics Offering, New Novelion CEO",2018-11-21 08:04:00-05:00,DRRX,negative
382999.0,DURECT Announces Amendment to Accelerate Ongoing Phase 2a Trial of DUR-928 in Alcoholic Hepatitis (AH) by Allowing Dosing of Severe AH Patients in Parallel to Moderate AH Patients,2018-11-19 08:06:00-05:00,DRRX,negative
383000.0,"The Daily Biotech Pulse: Mallinckrodt Faces FDA Panel, Reshape's Earnings, Vapotherm To Debut",2018-11-14 08:17:00-05:00,DRRX,neutral
383001.0,"Durect Q3 EPS $(0.02), Inline, Sales $8.036M Miss $8.57M Estimate",2018-11-07 16:38:00-05:00,DRRX,negative
383002.0,DURECT Announces Michael Arenberg CFO,2018-10-01 08:01:00-04:00,DRRX,neutral
383003.0,DURECT Announces Methydur Sustained Release Capsules Receive Marketing Authorization For ADHD In Taiwan,2018-09-18 08:00:00-04:00,DRRX,neutral
383004.0,"The Daily Biotech Pulse: FDA Snub For Gemphire, Ligand Earnings, Insmed's Antibiotic Faces FDA Panel",2018-08-07 08:23:00-04:00,DRRX,negative
383005.0,FDA Decision Sends Pain Therapeutics Reeling,2018-08-06 15:32:00-04:00,DRRX,negative
383006.0,44 Stocks Moving In Monday's Mid-Day Session,2018-08-06 12:39:00-04:00,DRRX,neutral
383007.0,Durect Corp shares are trading down 6.4% after the company's licensee Pain Therapeutics received CRL from FDA regarding REMOXY.,2018-08-06 10:20:00-04:00,DRRX,negative
383008.0,"Pain Therapeutics Gets a Complete Response Letter From the FDA Stating, 'The Data Submitted in [the] NDA Do Not Support the Conclusion That the Benefits of [REMOXY] Extended-Release Capsules Outweigh the Risks'",2018-08-06 07:10:00-04:00,DRRX,negative
383009.0,"The Daily Biotech Pulse: Denali's Parkinson's Candidate Clears Early-Stage Trials, Dexcom's Strong Quarter",2018-08-02 08:54:00-04:00,DRRX,positive
383010.0,"Durect Q2 EPS $(0.04) Beats $(0.06) Estimate, Sales $3.413M Miss $3.67M Estimate",2018-08-01 16:52:00-04:00,DRRX,negative
383011.0,"Benzinga's Biotech Pulse: Pfizer's Xeljanz Gets EU Nod, NewLink Losses Narrow, Neuralstem Commences Stroke Drug Trial",2018-08-01 09:01:00-04:00,DRRX,negative
383012.0,Attention Biotech Investors: Mark Your Calendar For These August PDUFA Dates,2018-08-01 07:38:00-04:00,DRRX,neutral
383013.0,"Benzinga Pro's Top 10 Most-Searched Tickers For Morning Of Mon., Jul. 30, 2018",2018-07-30 10:44:00-04:00,DRRX,positive
383014.0,"DURECT Corp. Shares Jump Up 19% Premarket After FDA Approved  New Drug Application For PERSERIS Schizophrenia Treatment, Triggering $5M Payout To Co.",2018-07-30 09:00:00-04:00,DRRX,positive
383015.0,DURECT Announces FDA Approval of Indivior's PERSERIS Extended-Release Injectable Suspension for the Treatment of Schizophrenia in Adults,2018-07-30 08:01:00-04:00,DRRX,positive
383016.0,"The Week Ahead In Biotech: Conferences, PDUFA Dates, Earnings And IPOs",2018-07-28 14:04:00-04:00,DRRX,neutral
383017.0,REMINDER: Durect Has FDA PDUFA Date For RBP-7000 Saturday July 28th,2018-07-27 17:07:00-04:00,DRRX,neutral
383018.0,"Benzinga's Daily Biotech Pulse: Achaogen To Trim Workforce By 28%, Amgen's Beat-And-Raise Quarter",2018-07-27 08:44:00-04:00,DRRX,neutral
383019.0,"The Week Ahead In Biotech: Conferences, PDUFA Dates, Clinical Trial Results, Earnings And IPOs",2018-07-22 17:03:00-04:00,DRRX,neutral
383020.0,A Look At Biotech In 2018 And The Biggest Catalysts Coming Up In The Second Half Of The Year,2018-07-05 12:25:00-04:00,DRRX,neutral
383021.0,Attention Biotech Investors: Mark Your Calendar For These July PDUFA Dates,2018-06-30 18:05:00-04:00,DRRX,neutral
383022.0,"Benzinga's Daily Biotech Pulse: Pain Therapeutics Drops 70%, Neon To Begin Trading",2018-06-27 08:14:00-04:00,DRRX,negative
383023.0,"Hearing Pain Therapeutics DURECT FDA Panel Voted Against Remoxy Approval In 3 For, 14 Against Approval",2018-06-26 16:21:00-04:00,DRRX,positive
383024.0,"Benzinga's Daily Biotech Pulse: Epidiolex, Roche's Influenza Drug Gets Priority Review Status, Xeris Jumps On Positive Trial Results",2018-06-26 08:34:00-04:00,DRRX,positive
383025.0,REMINDER: Pain Therapeutics and DURECT Have FDA AdCom Meeting For Remoxy Today BZ NOTE: A CRL Was Issued On Remoxy September 26th 2016,2018-06-26 07:33:00-04:00,DRRX,negative
383026.0,"The Week Ahead: Senate Weighs Sprint-T-Mobile Merger, Nike Earnings And A Slew Of IPOs",2018-06-25 14:00:00-04:00,DRRX,neutral
383027.0,"REMINDER Stocks With FDA Actions Expected This Week Include: Achaogen PDUFA Date for Plazomicin 6/25, Durect and Pain Therapeutics AdCom For Remoxy June 26, & GW Pharma PDUFA For Epidiolex in LG Syndrome June 27",2018-06-25 05:12:00-04:00,DRRX,negative
383028.0,"The Week Ahead In Biotech: Conferences, Clinical Trials And IPOs",2018-06-24 10:43:00-04:00,DRRX,neutral
383029.0,Attention Biotech Investors: Mark Your Calendar For These June PDUFA Dates,2018-06-01 13:22:00-04:00,DRRX,neutral
383030.0,"DURECT Announces Amendment to Licensing Agreement with Sandoz Related to POSIMIR, Co. Is Now eligible For Up To $30M In Milestone Payments, Down From $43M In Payments Before",2018-05-09 08:04:00-04:00,DRRX,positive
383031.0,"Durect Q1 EPS $(0.05) Beats $(0.06) Estimate, Sales $3.48M Miss $4.2M Estimate",2018-05-02 17:05:00-04:00,DRRX,negative
383032.0,DURECT Reports Patient Dosing In Phase 2a Trial Of DUR-928 In Alcoholic Hepatits,2018-04-25 08:27:00-04:00,DRRX,neutral
383033.0,32 Biggest Movers From Yesterday,2018-04-20 05:42:00-04:00,DRRX,neutral
383034.0,"DURECT Shares Up 6% After Co. Earlier Announced FDA Will Hold AdCom Meeting For Co.'s REMOXY ER, An Abuse-Deterrent, Extended Release Formation Of Oxycodone, On Jun. 26",2018-03-20 15:56:00-04:00,DRRX,positive
383035.0,"DURECT Reports FDA Panel Meeting For REMOXY ER Will Be Jun. 26, 2018; PDUFA Target Date Aug. 7, 2018",2018-03-20 08:01:00-04:00,DRRX,neutral
383036.0,44 Biggest Movers From Yesterday,2018-03-07 05:03:00-05:00,DRRX,neutral
383037.0,Analyst: Durect's Phase 2 Trials Are An Entry Point For Investors,2018-03-06 13:36:00-05:00,DRRX,neutral
383038.0,38 Stocks Moving In Tuesday's Mid-Day Session,2018-03-06 12:27:00-05:00,DRRX,neutral
383039.0,"Benzinga's Top Upgrades, Downgrades For March 6, 2018",2018-03-06 10:10:00-05:00,DRRX,positive
383040.0,"H.C. Wainwright Upgrades DURECT to Buy, Announces $3.50 Price Target",2018-03-06 07:13:00-05:00,DRRX,neutral
383041.0,"Durect Shares Up 8.4% Premarket After Co. Reported Late Thursday Q4 EPS $0.05, May Not Compare To $(0.06) Est., Sales $19.54M May Not Compare To $3.31M Est.",2018-03-02 09:21:00-05:00,DRRX,positive
383042.0,DURECT Announces Patient Dosing in Phase 2a Trial of DUR-928 in Primary Sclerosing Cholangitis,2018-02-26 08:02:00-05:00,DRRX,neutral
383043.0,"DURECT Announces Resubmission of REMOXY ER New Drug Application by its licensee, Pain Therapeutics",2018-02-14 08:01:00-05:00,DRRX,negative
383044.0,DURECT Announces the FDA Accepted the NDA for RBP-7000,2017-12-13 08:07:00-05:00,DRRX,positive
383045.0,66 Biggest Movers From Yesterday,2017-11-03 04:49:00-04:00,DRRX,neutral
383046.0,52 Stocks Moving In Thursday's Mid-Day Session,2017-11-02 12:29:00-04:00,DRRX,neutral
383047.0,"DURECT Reports Q3 EPS $0.04 vs $(0.06) Est., Sales $20.746M",2017-11-01 16:14:00-04:00,DRRX,neutral
383048.0,35 Biggest Movers From Friday,2017-10-23 06:07:00-04:00,DRRX,neutral
383049.0,Mid-Afternoon Market Update: Skechers Jumps On Earnings Beat; Del Taco Shares Slide,2017-10-20 14:33:00-04:00,DRRX,positive
383050.0,32 Stocks Moving In Friday's Mid-Day Session,2017-10-20 12:27:00-04:00,DRRX,neutral
383051.0,Mid-Day Market Update: Dow Surges Over 100 Points; DURECT Shares Plummet,2017-10-20 12:01:00-04:00,DRRX,positive
383052.0,Mid-Morning Market Update: Markets Open Higher; General Electric Earnings Miss Expectations,2017-10-20 10:13:00-04:00,DRRX,negative
383053.0,"Benzinga's Top Upgrades, Downgrades For October 20, 2017",2017-10-20 09:04:00-04:00,DRRX,positive
383054.0,Stifel Nicolaus Downgrades Durect to Hold,2017-10-20 07:24:00-04:00,DRRX,neutral
383055.0,H.C. Wainwright Downgrades Durect to Neutral,2017-10-20 07:14:00-04:00,DRRX,neutral
383056.0,UPDATE: DURECT Shares Now Down 54%,2017-10-19 18:31:00-04:00,DRRX,positive
383057.0,"DURECT Shares Resume Trade, Down 40.6%",2017-10-19 18:30:00-04:00,DRRX,positive
383058.0,DURECT Shares To Resume Trade At 6:30 p.m. EDT,2017-10-19 18:20:00-04:00,DRRX,positive
383059.0,DURECT Reports Says PERSIST Phase 3 Trial Of POSIMIR Did Not Meet Primary Efficacy Endpoint,2017-10-19 18:01:00-04:00,DRRX,neutral
383060.0,Durect Shares Halted News Pending,2017-10-19 17:28:00-04:00,DRRX,positive
383061.0,Durect Assigns Certain Patents to Indivior for $17.5M,2017-10-02 04:09:00-04:00,DRRX,positive
383062.0,DURECT Reports ORADUR-Methylphenidate ER Capsule Achieved Primary Endpoint In Phase 3 Study In ADHD In Taiwan,2017-08-08 08:35:00-04:00,DRRX,neutral
383063.0,"Zogenix Says on August 1, 2017 Terminated License Agreement Dated July 11, 2011 with Durrect Regarding Relday",2017-08-03 06:12:00-04:00,DRRX,positive
383064.0,15 Biggest Mid-Day Gainers For Wednesday,2017-07-12 12:17:00-04:00,DRRX,neutral
383065.0,"Benzinga's Top Upgrades, Downgrades For July 12, 2017",2017-07-12 09:23:00-04:00,DRRX,positive
383066.0,Stifel Nicolaus Upgrades Durect to Buy,2017-07-12 06:44:00-04:00,DRRX,neutral
383067.0,DURECT Announces Marketing Agreement with Novartis Subsidiary Sandoz is Effective,2017-06-19 07:07:00-04:00,DRRX,positive
383068.0,Durect Corp Pops to High of $1.53 on Volume,2017-06-01 15:01:00-04:00,DRRX,neutral
383069.0,"Durect and Novartis Co. Division Sandoz Sign Development, Commercialization Agreement In U.S. For Posimir",2017-05-11 08:47:00-04:00,DRRX,positive
383070.0,"DURECT Corp. Reports Q1 EPS $(0.06), Inline, Sales $4.567M vs $3.57M Est.",2017-05-10 16:07:00-04:00,DRRX,neutral
383071.0,"DURECT to get $20M Payment from a Division of Novartis, Up to $43M of Development Milestones, Up to $230M of Sales Milesones",2017-05-08 07:29:00-04:00,DRRX,neutral
383072.0,"Durect Shares Halted, News Pending",2017-05-08 07:00:00-04:00,DRRX,positive
383073.0,DURECT Offers Data from Phase 1b Study of DUR-928 in NASH: 'Biomarker analysis provides evidence for a potential therapeutic effect of DUR-928 in NASH',2017-04-24 08:07:00-04:00,DRRX,neutral
383074.0,"DURECT Corporation Reports Q4 EPS $(0.06) vs. $(0.06) Est., Sales $3.51M vs. $3.61M Est.",2017-03-14 16:03:00-04:00,DRRX,neutral
383075.0,"Earnings Scheduled For March 14, 2017",2017-03-14 04:44:00-04:00,DRRX,neutral
383076.0,"Benzinga's Top Upgrades, Downgrades For February 28, 2017",2017-02-28 09:30:00-05:00,DRRX,positive
383077.0,"H.C. Wainwright Initiates Coverage On Durect With Buy, Announces $3 Price Target",2017-02-28 07:05:00-05:00,DRRX,neutral
383078.0,"DURECT Corp. Offers Update on DUR-928 Development Program, Discusses Phase 1b Trial in Patients with NASH, in Patients with Impaired Kidney Function",2017-01-30 08:11:00-05:00,DRRX,neutral
383079.0,Watch These 7 Huge Call Purchases In Thursday Trade,2016-12-22 04:05:00-05:00,DRRX,positive
383080.0,Option Alert: DRRX Jul17 2.5 Calls: 2755 @  ASK  $0.30: 2800 traded vs 734 OI:  Earnings 2/27 After Close (est)  $1.31 Ref,2016-12-21 09:34:00-05:00,DRRX,positive
383081.0,Broadfin Capital Reports 6.14% Passive Stake In Durect Corp in 13G,2016-11-21 13:01:00-05:00,DRRX,positive
383082.0,Stifel Healthcare Conference Today,2016-11-15 10:53:00-05:00,DRRX,neutral
383083.0,15 Biggest Mid-Day Gainers For Tuesday,2016-11-01 13:55:00-04:00,DRRX,neutral
383084.0,"DURECT Reports Q3 Loss/Share $0.06 vs Est Loss/Share $0.07, Revenue $3.7M vs $3.72M Est",2016-10-31 16:17:00-04:00,DRRX,neutral
383085.0,Durect Reports Positive Data From DUR-028 Development Program,2016-10-31 16:15:00-04:00,DRRX,positive
383086.0,15 Biggest Mid-Day Gainers For Tuesday,2016-09-27 12:41:00-04:00,DRRX,neutral
383087.0,12 Biggest Mid-Day Losers For Monday,2016-09-26 13:10:00-04:00,DRRX,negative
383088.0,DURECT Shares Tumble 32% as Co. Announced Licensee Pain Therapeutics Received FDA CRL for REMOXY ER,2016-09-26 12:52:00-04:00,DRRX,negative
383089.0,Mid-Day Market Update: Crude Oil Up 3.3%; Chemtura Shares Surge Following Acquisition News,2016-09-26 12:49:00-04:00,DRRX,negative
383090.0,Mid-Morning Market Update: Markets Open Lower; Cal-Maine Posts Wider-Than-Expected Loss,2016-09-26 10:04:00-04:00,DRRX,negative
383091.0,15 Stocks Moving In Monday's Pre-Market Session,2016-09-26 08:30:00-04:00,DRRX,neutral
383092.0,"Pain Therapeutics, DURECT Corporation, Array BioPharma to Resume at 7:30 AM ET",2016-09-26 07:16:00-04:00,DRRX,negative
383093.0,"25 Stocks Which Rallied Four Days, Then Sold Off Yesterday",2016-09-22 09:47:00-04:00,DRRX,neutral
383094.0,"DURECT Corp. Reports Q2 EPS $(0.07) vs. Est. $(0.06), Rev. $3.157M vs. Est. $3.69M",2016-08-01 16:38:00-04:00,DRRX,neutral
383095.0,Durect Corp Shares Spike to High og $1.48 on Vol; Move Related to Press Release from Third Party Streetwise Reports,2016-07-14 14:39:00-04:00,DRRX,positive
383096.0,"DURECT Reports Tentative Date for FDA Panel Meeting Aug. 5, 2016, No Change to PDUFA Date of Sept. 25, '16",2016-05-19 09:06:00-04:00,DRRX,negative
383097.0,"DURECT Corp Reports Inline Q1 EPS $(0.06), Sales $3.608M Vs Est $4.09M",2016-05-05 17:29:00-04:00,DRRX,neutral
383098.0,"21 April Fund Ltd Buys 5,500,000 Shares of DURECT @$1.25/Share -Form 4",2016-04-27 10:58:00-04:00,DRRX,positive
383099.0,DURECT Prices 12M Share Offering At $1.25/Share,2016-04-26 09:04:00-04:00,DRRX,positive
383100.0,"DURECT Announces Proposed Public Offering of Common Stock, Aggregate Price $400K",2016-04-25 16:02:00-04:00,DRRX,neutral
383101.0,"Rodman & Renshaw Initiates Coverage on Durect at Buy, Announces $4.00 PT",2016-04-25 07:00:00-04:00,DRRX,neutral
383102.0,Durect Corp Filings Says Co Received Letter From FDA Advising Co Make Amendments To PERSIST Trial,2016-04-07 17:20:00-04:00,DRRX,neutral
383103.0,"UPDATE: DURECT Says Change Will Add Time, Cost to Close PERSIST Trial, But Co. Believes Positive Outcome from Trial Design Will Result in Stronger NDA Filing",2016-04-07 17:03:00-04:00,DRRX,positive
383104.0,UPDATE: DURECT Says FDA Recommended Incorporation of Standard Bupivacaine HCI as Active Control,2016-04-07 17:01:00-04:00,DRRX,positive
383105.0,DURECT Offers Program Update for POSIMIR: Co. Received Letter from FDA Advising Amendments to PERSIST Trial,2016-04-07 17:01:00-04:00,DRRX,neutral
383106.0,"DURECT Reports Licensee, Pain Therapeutics, Resubmitted REMOXY NDA to FDA",2016-03-29 11:15:00-04:00,DRRX,negative
383107.0,"Chairman Theeuwes Buys 70,000 Shares Of DURECT @$1.41/Share -Form 4",2016-03-16 14:47:00-04:00,DRRX,positive
383108.0,"Director Neukermans Buys 18,000 Shares Of DURECT @$1.39/Share -Form 4",2016-03-16 13:39:00-04:00,DRRX,positive
383109.0,DURECT Announces Positive Phase 1 Data for DUR-928,2016-01-06 08:00:00-05:00,DRRX,positive
383110.0,Mid-Morning Market Update: Markets Mostly Flat; Krispy Kreme Misses Q2 Estimates,2015-09-10 10:14:00-04:00,DRRX,negative
383111.0,"Durect Reports Q2 Loss $0.05 vs Est Loss $0.06, Sales $4.441M Vs Est $55.01M",2015-08-03 16:14:00-04:00,DRRX,negative
383112.0,"Cantor Analyst: Durect Is Worth $3/Share, So Buy It",2015-06-24 13:53:00-04:00,DRRX,positive
383113.0,DURECT Announces Plans for a New POSIDUR Clinical Trial,2015-06-23 08:01:00-04:00,DRRX,neutral
383114.0,Mid-Afternoon Market Update: Standard Pacific Rises On Ryland Merger Deal; Micron Shares Slip,2015-06-15 15:58:00-04:00,DRRX,positive
383115.0,Mid-Afternoon Market Update: Wingstop Shares Surge in Stock Market Debut; ExOne Shares Tumble,2015-06-12 15:17:00-04:00,DRRX,positive
383116.0,DURECT Corp. Reports Positive Results from DUR-928 Multi-Dose Ph,2015-05-18 08:32:00-04:00,DRRX,positive
383117.0,DURECT Initiates DUR-928 Multi-Dose Phase 1 Study,2015-03-30 08:33:00-04:00,DRRX,neutral
383118.0,Zogenix Announces First Patient Dosed in Relday Multi-Dose Clinical Study,2015-03-26 09:04:00-04:00,DRRX,neutral
383119.0,"Durect Corp Director Benito Buys 40,000 Shares @$1.81/Share -Form 4",2015-03-10 20:22:00-04:00,DRRX,positive
383120.0,Morning Market Gainers,2015-03-03 09:52:00-05:00,DRRX,neutral
383121.0,"Cantor Fitzgerald Upgrades Durect to Buy, Raises PT to $2.00",2015-03-03 06:36:00-05:00,DRRX,neutral
383122.0,"Durect Corp Reports Q4 EPS -$0.05 Vs Est -$0.06, Sales $4.27M Vs Est $4.32M",2015-03-02 16:04:00-05:00,DRRX,neutral
383123.0,DURECT Enter Licensing Agreement With Santen Pharmaceutical Co,2014-12-16 08:03:00-05:00,DRRX,positive
383124.0,DURECT Offers Update on POSIDUR Program: Certain Scenario Shows Only One Added Test Needed,2014-11-11 16:12:00-05:00,DRRX,positive
383125.0,Morning Market Losers ,2014-10-27 10:07:00-04:00,DRRX,negative
383126.0,Shares of Durect Corp. Plunge Nearly 40% Upon Resumption,2014-10-27 08:45:00-04:00,DRRX,positive
383127.0,"Durect Corp. Offers Update on REMOXY, POSIDUR Programs: Will Discontinue Deal",2014-10-27 08:06:00-04:00,DRRX,neutral
383128.0,CORRECTION: Shares of Durect Corp. Halted News Pending,2014-10-27 08:05:00-04:00,DRRX,positive
383129.0,"Shares of Durect Corp., Pain Therapeutics Halted News Pending",2014-10-27 07:59:00-04:00,DRRX,negative
383130.0,"Durect Corporation Reports Q2 EPS of $(0.05), Inline; Revenue of $4.58M vs $3.89M Est",2014-08-07 16:53:00-04:00,DRRX,neutral
383131.0,DURECT Secures $20M Debt Financing,2014-06-26 16:07:00-04:00,DRRX,negative
383132.0,"Form 8-K from Durect Shows Co. Expecting to Formally Request Face-to-Face Meeting with FDA Net Week, Expecting One Remoxy Study Concluded in April, Three in June",2014-05-01 16:29:00-04:00,DRRX,neutral
383133.0,Durect Corporation Reports Q1 EPS of $(0.03) vs $(0.05) Est; Revenue of $6.30M vs $4.12M Est,2014-05-01 16:28:00-04:00,DRRX,neutral
383134.0,Durect Corporation Reports Q4 EPS of $(0.05) vs $(0.06) Est; Revenue of $4.30M vs $2.79M Est,2014-02-27 16:09:00-05:00,DRRX,neutral
383135.0,Shares of Durect Corp. Resume Trade Down ~35%,2014-02-12 17:15:00-05:00,DRRX,positive
383136.0,Durect Corp. Shares to Resume Trade at 5:15PM EST,2014-02-12 16:52:00-05:00,DRRX,positive
383137.0,"Durect Corp. Receives CRL from FDA on POSIDUR, Says FDA Cannot Approved NDA in Present Form",2014-02-12 16:43:00-05:00,DRRX,negative
383138.0,Durect Corp. Halted News Pending,2014-02-12 16:10:00-05:00,DRRX,neutral
383139.0,"Impax & Durect Sign $63M Deal to Develop, Commercialize Eladur Pain Patch",2014-01-07 08:04:00-05:00,DRRX,negative
383140.0,Durect Files $101M Mixed Securities Shelf,2013-12-20 17:15:00-05:00,DRRX,positive
383141.0,"Durect Corporation Reports Q3 EPS of $(0.06), Inline; Revenue of $2.97M vs $3.54M Est",2013-11-04 16:50:00-05:00,DRRX,neutral
383142.0,Pfizer Says Proceeding with Remoxy Development,2013-10-22 08:12:00-04:00,DRRX,neutral
383143.0,Pain Therapeutics Says Pfizer Elects to Continue Development of REMOXY(R) ,2013-10-22 08:05:00-04:00,DRRX,negative
383144.0,UPDATE: FDA Will Be Holding an Official Briefing at 12:45PM EDT to Discuss an Undisclosed Topic,2013-09-10 12:07:00-04:00,DRRX,neutral
383145.0,FDA Traders Considering Admin. Updates Labels on Long-Acting Painkillers,2013-09-10 12:04:00-04:00,DRRX,neutral
383146.0,"Market Wrap for Friday, August 16: Pullback In Equities Continues To Close Week",2013-08-16 17:17:00-04:00,DRRX,neutral
383147.0,UPDATE: Durect Provides Update of Programs,2013-08-05 16:20:00-04:00,DRRX,neutral
383148.0,"Durect Corporation Reports Q2 EPS of $(0.05), Inline; Revenue of $3.92M vs $3.42M Est",2013-08-05 16:07:00-04:00,DRRX,neutral
383149.0,DURECT Announces FDA Acceptance of New Drug Application (NDA) Submission for POSIDURÂ® (SABERÂ®-Bupivacaine) ,2013-06-20 07:07:00-04:00,DRRX,positive
383150.0,"Mid-Morning Market Update: Gold Futures See Sharp Decline, Ubiquity Networks Reports Growth for Second Straight Quarter",2013-05-10 10:47:00-04:00,DRRX,positive
383151.0,Morning Market Losers,2013-05-10 10:13:00-04:00,DRRX,negative
383152.0,Durect Corporation Reports Q1 EPS of $(0.05) vs $(0.07) Est; Revenue of $4.20M vs $3.87M Est,2013-05-02 16:23:00-04:00,DRRX,neutral
383153.0,"Traders Attributing Strength in Pain Therapeutics, Durect to Comments from Pfizer Exec on Call Co. Optimistic About Prospects for Improved Tamper-Resistant Pain Drugs",2013-04-30 11:04:00-04:00,DRRX,positive
383154.0,"UPDATE: Pain Therapeutics Shares Now Up 35%, Durect Shares Up 47%",2013-04-30 10:47:00-04:00,DRRX,neutral
383155.0,"Durect Corp. Shares Resume Trade, Now Up 32%",2013-04-30 10:45:00-04:00,DRRX,positive
383156.0,"Durect Halted on Circuit Breaker, Now Up 32%",2013-04-30 10:40:00-04:00,DRRX,neutral
383157.0,DURECT Announces Submission of NDA for POSIDUR,2013-04-16 07:29:00-04:00,DRRX,neutral
383158.0,"Stifel Nicolaus Initiates Coverage on Durect Corporation at Buy, Announces $3.00 PT",2013-03-25 08:46:00-04:00,DRRX,neutral
383159.0,Durect Corporation Reports Q4 EPS of $(0.06) vs $(0.05) Est,2013-02-28 16:09:00-05:00,DRRX,neutral
383160.0,Zogenix Announces Positive Relday Phase 1 Clinical Trial Results,2013-01-03 07:40:00-05:00,DRRX,positive
383161.0,From Earlier: Durect Prices 14M Shares at $0.90/Share,2012-12-06 08:41:00-05:00,DRRX,positive
383162.0,From Earlier: Durect Prices 14M Shares at $0.90/Share,2012-12-06 08:41:00-05:00,DRRX,positive
383163.0,DURECT Prices 14M Share Offering at $0.90 per Share,2012-12-06 07:34:00-05:00,DRRX,positive
383164.0,DURECT Prices 14M Share Offering at $0.90/Share,2012-12-06 07:16:00-05:00,DRRX,positive
383165.0,Durect Reports Q3 EPS $-0.05 vs $-0.05 Est; Revenues $3.8M vs $5.49M Est,2012-11-05 16:24:00-05:00,DRRX,neutral
383166.0,CK Cooper Downgrades Durect from Buy to Hold,2012-11-01 12:13:00-04:00,DRRX,neutral
383167.0,"Durect Shares Have Resumed Following Circuit Breaker, Stock Down 39%",2012-11-01 11:03:00-04:00,DRRX,positive
383168.0,"Durect Halted Again on Circuit Breaker, Now Down Just 14%",2012-11-01 10:58:00-04:00,DRRX,neutral
383169.0,Durect Shares Resume,2012-11-01 10:57:00-04:00,DRRX,positive
383170.0,"Durect Shares Halted on Circuit Breaker, Now Down 40%",2012-11-01 10:54:00-04:00,DRRX,positive
383171.0,Benzinga's Top Initiations,2012-08-17 07:32:00-04:00,DRRX,positive
383172.0,UPDATE: CK Cooper & Company Initiates DURECT Corporation at Buy on Potential Drug Approval  ,2012-08-17 06:18:00-04:00,DRRX,positive
383173.0,"C.K. Cooper & Company Initiates Coverage Durect at Buy, Announces PT of $3",2012-08-17 05:49:00-04:00,DRRX,neutral
383174.0,DURECT Announces Intent to Submit NDA for POSIDURâ„¢ for Post-Operative Analgesia,2012-08-06 16:17:00-04:00,DRRX,neutral
383175.0,Durect Reports Q2 EPS $0.00 vs $-0.05 Est,2012-08-06 16:08:00-04:00,DRRX,neutral
383176.0,"Benzinga's Microcap Movers for Friday July 20, 2012",2012-07-21 17:23:00-04:00,DRRX,neutral
383177.0,"Benzinga's Microcap Movers for Wednesday May 30, 2012",2012-05-30 21:28:00-04:00,DRRX,neutral
383178.0,Zogenix Submits IND for Second DosePro(R) Candidate Relday(TM) ,2012-05-30 07:32:00-04:00,DRRX,neutral
383179.0,Pain Therapeutics Announces Four U.S. Patents Issued for REMOXY  ,2012-05-03 08:41:00-04:00,DRRX,negative
383180.0,DURECT Announces Issuance of U.S. Patents Covering ORADUR Technology ,2012-05-03 08:15:00-04:00,DRRX,neutral
383181.0,DURECT Receives Back U.S. and Canadian Product Rights to POSIDURâ„¢,2012-03-29 16:16:00-04:00,DRRX,neutral
383182.0,Pfizer Terminates Development and License Agreement Between Alpharma Ireland and DURECT,2012-03-01 16:40:00-05:00,DRRX,positive
383183.0,Durect Says Pfizer Ending Licese Pact,2012-03-01 16:40:00-05:00,DRRX,neutral
383184.0,DURECT Receives Back European Product Rights to POSIDUR,2012-01-30 16:15:00-05:00,DRRX,neutral
383185.0,Durect Corporation Resumes Trading,2012-01-05 16:45:00-05:00,DRRX,neutral
383186.0,Durect Corporation Resumes Trading,2012-01-05 16:43:00-05:00,DRRX,neutral
383187.0,PREVIEW: Durect to Resume Trading at 4:45pm,2012-01-05 16:19:00-05:00,DRRX,neutral
383188.0,DURECT Announces Top-line Data from BESST; Did Not Reach Statistical Significance  ,2012-01-05 16:16:00-05:00,DRRX,negative
383189.0,DURECT Completes Enrollment in Pivotal U.S. Phase III Trial for POSIDUR,2011-09-06 07:31:00-04:00,DRRX,neutral
383190.0,Zogenix to Develop and Commercialize Proprietary Long-Acting Risperidone Formulation for Needle-Free Subcutaneous Administration Using the DosePro Delivery System and DURECT's SABER Depot Technology,2011-07-12 07:33:00-04:00,DRRX,neutral
383191.0,Piper Jaffray Maintains OW Rating and $4 PT on Durect,2011-06-27 08:16:00-04:00,DRRX,neutral
383192.0,Top Percentage Gainers and Losers as of 2pm 6/24/11,2011-06-24 14:03:00-04:00,DRRX,negative
383193.0,Top Percentage Gainers and Losers as of 12:15pm 6/24/11,2011-06-24 12:17:00-04:00,DRRX,negative
383194.0,Durect Corporation and Pain Therapeutics Resume Trading,2011-06-24 08:30:00-04:00,DRRX,negative
383195.0,Benzinga's Top Pre-Market NASDAQ Losers,2011-06-24 08:26:00-04:00,DRRX,negative
383196.0,PREVIEW: Durect Corporation and Pain Therapeutics to Resume at 8:30 a.m. ET,2011-06-24 08:23:00-04:00,DRRX,negative
383197.0,"Durect Corporation Halted, Pending News",2011-06-24 07:52:00-04:00,DRRX,neutral
383198.0,DURECT Corporation Down Nearly 20% Pre-Market on FDA Rejection,2011-06-24 07:24:00-04:00,DRRX,negative
383199.0,"FDA PDUFA Dates Scheduled for Tomorrow: LCI, DRRX, and PITE",2011-06-22 09:30:00-04:00,DRRX,neutral
383200.0,DURECT Announces Resignation of Chief Medical Officer,2011-06-02 16:15:00-04:00,DRRX,negative
383201.0,Piper Jaffray Overweight On DURECT Corporation  (DRRX),2011-05-06 07:50:00-04:00,DRRX,negative
383202.0,"Top Percentage Gainers And Losers As Of 2 p.m. 4/12/2011 (CYH, THC, IDIX, BAC, SKH, JPM, BIO, REDF, DEER, THC, CYTX, CCRT, WMS, EXTR, LFT, SB, DRRX, BRNC, MCRL)",2011-04-12 14:09:00-04:00,DRRX,negative
383203.0,"Top Percentage Gainers And Losers As Of 12 p.m. 4/12/2011 (SKH, JPM, CYH, THC, SIFY, TIBX, HPQ, IDIX, BAC, CCRT, WMS, EXTR, SB, PSTR, GLUU, UAL, GIL, DRRX, SGI, AIB)",2011-04-12 12:09:00-04:00,DRRX,negative
383204.0,DURECT Announces ELADUR Phase II Study Results in Chronic Low Back Pain  ,2011-04-11 16:16:00-04:00,DRRX,negative
383205.0,DURECT Announces ELADUR  Phase II Study Results in Chronic Low Back Pain ,2011-04-11 16:16:00-04:00,DRRX,negative
383206.0,DURECT Corporation Reports Q4 EPS of $(0.06),2011-03-02 16:10:00-05:00,DRRX,neutral
383207.0,DURECT Announces Launch of First FDA Approved SABER Injectable Peptide Product ,2011-02-08 16:22:00-05:00,DRRX,positive
383208.0,Hospira Misses; 2011 View Weak - Analyst Blog,2011-02-02 13:31:00-05:00,DRRX,negative
383209.0,Hospira Misses; 2011 View Weak - Analyst Blog,2011-02-02 13:15:00-05:00,DRRX,negative
383210.0,DURECT Announces REMOXY New Drug Application Accepted by the FDA ,2011-01-27 08:46:00-05:00,DRRX,positive
383211.0,Pfizer Extends King Tender Offer - Analyst Blog,2011-01-24 15:01:00-05:00,DRRX,positive
383212.0,Pfizer Extends King Tender Offer - Analyst Blog,2011-01-24 14:47:00-05:00,DRRX,positive
383213.0,King Pharma Resubmits Remoxy NDA - Analyst Blog,2010-12-29 10:03:00-05:00,DRRX,neutral
383214.0,King Pharma Resubmits Remoxy NDA - Analyst Blog,2010-12-29 09:45:00-05:00,DRRX,neutral
383215.0,A Peek Into The Market Before The Trading Starts,2010-12-27 08:06:00-05:00,DRRX,neutral
383216.0,REMOXY Drug Application Resubmitted,2010-12-27 07:18:00-05:00,DRRX,neutral
383217.0,DURECT Corporation Announces Third Quarter 2010 Financial Results,2010-11-03 16:41:00-04:00,DRRX,neutral
383218.0,Jefferies Reiterates Buy Rating on DURECT Corp. (DRRX),2010-08-05 09:54:00-04:00,DRRX,neutral
383219.0,Jeffries Keeps Its Buy Rating On DRRX,2010-08-05 08:05:00-04:00,DRRX,neutral
383220.0,How Will Obama-Care Play Into The Markets And ETFs?,2010-03-21 21:50:00-04:00,DRRX,positive
